Mastodon

Lidamitol tabs (Tablets) Instructions for Use

Marketing Authorization Holder

Grotex, LLC (Russia)

ATC Code

M03BX04 (Tolperisone)

Active Substance

Tolperisone (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Lidamitol tabs Film-coated tablets, 150 mg: 10, 20, or 30 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets

Tolperisone 150 mg

10 pcs. – blister packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – blister packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription

Clinical-Pharmacological Group

Centrally acting muscle relaxant

Pharmacotherapeutic Group

Centrally acting muscle relaxants; other centrally acting muscle relaxants

Pharmacological Action

Centrally acting muscle relaxant. The reduction of pathologically increased skeletal muscle tone is explained by the ability of tolperisone to suppress spinal polysynaptic reflexes and its inhibitory effect on the caudal part of the reticular formation. It has central n-cholinoblocking properties. It does not have a significant effect on the peripheral parts of the nervous system. It has a weak antispasmodic and vasodilating effect.

Indications

Spinal and cerebral palsies (hypertonia, muscle spasm, spinal automatism; limb contracture).

Diseases accompanied by dystonia, rigidity, muscle spasm; obliterating arterial diseases: obliterating atherosclerosis of limb vessels, diabetic angiopathy, obliterating thromboangiitis (Buerger’s disease), Raynaud’s syndrome.

Consequences of disorders of vascular innervation (acrocyanosis, intermittent angioneurotic dysbasia).

Extrapyramidal disorders (postencephalitic and atherosclerotic parkinsonism).

Postthrombotic disorders of lymph circulation and venous circulation, trophic leg ulcer, infantile spastic paralysis (Little’s disease), epilepsy, encephalopathy of vascular origin; hypertonia combined with a violation of muscle tone of another type.

ICD codes

ICD-10 code Indication
G21.3 Postencephalitic parkinsonism
G21.4 Vascular parkinsonism
G24 Dystonia (including dyskinesia)
G40 Epilepsy
G80 Cerebral palsy
G81.1 Spastic hemiplegia
G82.1 Spastic paraplegia
G82.4 Spastic tetraplegia
G93.4 Unspecified encephalopathy
I73.0 Raynaud's syndrome
I73.1 Obliterative thromboangiitis [Buerger's disease]
I73.8 Other specified peripheral vascular diseases
I73.9 Peripheral vascular disease, unspecified (including intermittent claudication, arterial spasm)
I79.2 Peripheral angiopathy in diseases classified elsewhere (including diabetic angiopathy)
I87.0 Postthrombotic syndrome
L98.4 Chronic skin ulcer, not elsewhere classified
R25.2 Cramp and spasm
ICD-11 code Indication
4A44.8 Thromboangiitis obliterans
7A82 Sleep related leg cramps
8A00.23 Vascular parkinsonism
8A00.2Y Other specified secondary parkinsonism
8A02.Z Dystonic disorders, unspecified
8A6Z Epilepsy or epileptic seizures, unspecified
8D2Z Cerebral palsy, unspecified
8E47 Encephalopathy, not elsewhere classified
8E4A.0 Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord
8E63 Post-cardiopulmonary bypass encephalopathy
BD42.0 Raynaud's disease
BD42.1 Raynaud's syndrome
BD42.Z Raynaud's phenomenon, unspecified
BD4Z Chronic obliterative arterial diseases, unspecified
BD53.Y Other specified secondary involvement of arteries and arterioles
BD5Z Diseases of arteries or arterioles, unspecified
BD74.Z Chronic venous insufficiency of lower extremities, unspecified
EA40 Tropical phagedenic ulcer
EF60 Ischemic ulceration of the skin
EG00 Dilation of skin vessels of the extremities
EM0Z Unspecified skin disorder
MB40.7 Acroparesthesia
MB47.3 Convulsion or spasm
MB50.1 Spastic tetraplegia
MB53.2 Spastic hemiplegia
MB56 Paraplegia
ME60.2 Ulcerative skin lesion of unspecified nature

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer Lidamitol tablets orally with a full glass of water after a meal to minimize potential gastrointestinal discomfort.

Initiate therapy with an initial dose of 50 mg (one-third of a 150 mg tablet) taken two to three times daily.

Gradually titrate the dose upward based on individual patient tolerance and therapeutic response.

The standard maintenance dose for adults is 150 mg (one tablet) taken two to three times daily.

The maximum total daily dose should not exceed 450 mg, equivalent to three 150 mg tablets.

For intramuscular administration, inject 100 mg (1 ml of solution) twice daily deep into the muscle.

For intravenous administration, inject 100 mg (1 ml of solution) once daily as a single, slow injection.

Adhere strictly to the prescribed dosage and frequency; do not adjust the regimen without consulting a physician.

Discontinuation should be performed gradually under medical supervision if long-term therapy is concluded.

Adverse Reactions

Possible headache, myasthenia, arterial hypotension, nausea, vomiting, gastralgia, allergic reactions (anaphylactic shock, bronchospasm, urticaria, erythematous rash, skin itching).

Contraindications

Myasthenia, pregnancy, lactation period, children and adolescents under 18 years of age, hypersensitivity to tolperisone.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation.

Pediatric Use

Contraindicated in children under 1 year of age.

Special Precautions

Effect on ability to drive vehicles and mechanisms

Use with caution in patients whose activities require increased attention and speed of psychomotor reactions.

Drug Interactions

The effect of tolperisone is enhanced with simultaneous use with drugs for general anesthesia, peripheral muscle relaxants, psychoactive drugs, and with clonidine.

Storage Conditions

Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS